What Roivant Sciences Ltd's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 19 | 116 |
| Total trades | 55 | 232 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 1,510,089 | 23,681,614 |
| Disposed | 1,865,662 | 44,144,224 |
| Net activity | −355,573 | −20,462,610 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Oren Ilan | Director | Oct 23 | Grant / award · A | +810 | — | — | 124,490 |
| Momtazee James C | Director | Oct 23 | Withheld — tax / exercise cost · F | −77 | $36.49 | −$2.81K | 112,265 |
| Momtazee James C | Director | Oct 23 | Grant / award · A | +383 | — | — | 112,342 |
| Epperly Melissa B, | Director | Oct 23 | Withheld — tax / exercise cost · F | −116 | $36.49 | −$4.23K | 15,351 |
| Epperly Melissa B, | Director | Oct 23 | Grant / award · A | +513 | — | — | 15,467 |
| Venker Eric | President & Immunovant CEO | Oct 20 | Disclosed 10b5-1 sale · S | −14,144 | $35.42 | −$501K | 1,399,154 |
| Venker Eric | President & Immunovant CEO | Oct 20 | Disclosed 10b5-1 sale · S | −185,856 | $35.09 | −$6.52M | 1,413,298 |
| Sukhatme Mayukh | President & CIO | Oct 16 | Withheld — tax / exercise cost · F | −19,976 | $33.53 | −$670K | 18,563,884 |
| Gline Matthew | CEO | Oct 16 | Withheld — tax / exercise cost · F | −34,638 | $33.53 | −$1.16M | 16,549,136 |
| Epperly Melissa B, | Director | Oct 01 | Disclosed 10b5-1 sale · S | −900 | $36.57 | −$32.9K | 14,954 |
| Epperly Melissa B, | Director | Oct 01 | Disclosed 10b5-1 sale · S | −16,850 | $36.08 | −$608K | 15,854 |
| Epperly Melissa B, | Director | Oct 01 | Exercise / conversion · M | +17,750 | $4.46 | +$79.2K | 32,704 |
| Torti Frank | President and Vant Chair | Sep 30 | Withheld — tax / exercise cost · F | +40,309 | $36.57 | +$1.47M | 13,495,893 |
| Gline Matthew | CEO | Sep 30 | Withheld — tax / exercise cost · F | −76,171 | $36.57 | −$2.79M | 16,583,774 |
| Venker Eric | President & Immunovant CEO | Sep 30 | Disclosed 10b5-1 sale · S | −200,000 | $36.62 | −$7.32M | 1,599,154 |
| Venker Eric | President & Immunovant CEO | Sep 30 | Exercise / conversion · M | +200,000 | $3.85 | +$770K | 1,799,154 |
| Sukhatme Mayukh | President & CIO | Sep 30 | Withheld — tax / exercise cost · F | −46,879 | $36.57 | −$1.71M | 18,583,860 |
| Humes Jennifer | Chief Accounting Officer | Sep 20 | Withheld — tax / exercise cost · F | −3,880 | $39.77 | −$154K | 106,419 |
| Pulik Richard | CFO | Sep 20 | Withheld — tax / exercise cost · F | −2,129 | $39.77 | −$84.7K | 269,681 |
| Momtazee James C | Director | Sep 16 | Grant / award · A | +5,054 | — | — | 111,959 |
Loading...
